Irwin Naturals (IWIN) 주식 개요는 미국, 캐나다 및 전 세계에서 비타민 및 기타 건강 보조 식품을 개발 및 유통하는 회사입니다. 자세히 보기IWIN 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적0/6재무 건전성1/6배당0/6위험 분석부채는 operating cash flow로 충분히 감당되지 않습니다.지난 5년간 매년 수익이 87.1% 감소했습니다.의미 있는 시가총액이 없습니다(CA$1M)주식은 유동성이 매우 낮습니다+ 위험 1건 추가모든 위험 점검 보기IWIN Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.3099.5% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-20m99m2016201920222025202620282031Revenue US$86.7mEarnings US$9.2mAdvancedSet Fair ValueView all narrativesIrwin Naturals, Inc. 경쟁사Vitality ProductsSymbol: TSXV:VPIMarket cap: CA$621.2kNeutriSci InternationalSymbol: TSXV:NU.HMarket cap: CA$892.1kMercanto HoldingsSymbol: TSXV:MUSHMarket cap: CA$6.5mPsyched WellnessSymbol: CNSX:PSYCMarket cap: CA$6.1m가격 이력 및 성과Irwin Naturals 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$0.3052주 최고가CA$1.4652주 최저가CA$0.05베타-0.131개월 변동0%3개월 변동0%1년 변동-77.78%3년 변동n/a5년 변동n/aIPO 이후 변동-89.09%최근 뉴스 및 업데이트New Risk • Apr 19New major risk - Revenue and earnings growthEarnings have declined by 87% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Shares are highly illiquid. Earnings have declined by 87% per year over the past 5 years. Market cap is less than US$10m (CA$471.7k market cap, or US$343.2k).Board Change • Apr 11No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman & CEO Klee Irwin is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.공시 • Mar 30+ 1 more updateIrwin Naturals, Inc. Announces Directors ChangesIrwin Naturals, Inc. announced that Rod Kight and Sheri Orlowitz have tendered their resignations as directors of the Company effective February 14, 2024 . The Company thanks Mr. Kight and Ms. Orlowitz for their contributions to the Company and wishes them the best of luck in their future endeavors. Klee Irwin will remain as chairman of the Board of Directors. Moreover, the Company announced the new board members that have been elected to fill the aforementioned vacancies, Luke Lokhorst and Lyle Maxson. Their terms on the board began February 14, 2024. Lyle Maxson is at the forefront healthcare innovation including founding and serving as a board member on companies leveraging Artificial Intelligence and plant medicine to push healthcare system forward. Luke Lokhorst holds a Masters Degree in International Business and Sustainable Finance and are excited to add him to the leadership team.Reported Earnings • Nov 24Third quarter 2023 earnings released: US$0.56 loss per share (vs US$0.49 loss in 3Q 2022)Third quarter 2023 results: US$0.56 loss per share (further deteriorated from US$0.49 loss in 3Q 2022). Revenue: US$19.1m (down 13% from 3Q 2022). Net loss: US$1.74m (loss widened 158% from 3Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Personal Products industry in North America.New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Market cap is less than US$10m (CA$1.85m market cap, or US$1.34m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).공시 • Aug 27Irwin Naturals Announces Goodwill Impairment for the Second Quarter Ended June 30, 2023Irwin Naturals Inc. announced Goodwill impairment of $9,112,000 for the second quarter ended June 30, 2023.더 많은 업데이트 보기Recent updatesNew Risk • Apr 19New major risk - Revenue and earnings growthEarnings have declined by 87% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Shares are highly illiquid. Earnings have declined by 87% per year over the past 5 years. Market cap is less than US$10m (CA$471.7k market cap, or US$343.2k).Board Change • Apr 11No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman & CEO Klee Irwin is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.공시 • Mar 30+ 1 more updateIrwin Naturals, Inc. Announces Directors ChangesIrwin Naturals, Inc. announced that Rod Kight and Sheri Orlowitz have tendered their resignations as directors of the Company effective February 14, 2024 . The Company thanks Mr. Kight and Ms. Orlowitz for their contributions to the Company and wishes them the best of luck in their future endeavors. Klee Irwin will remain as chairman of the Board of Directors. Moreover, the Company announced the new board members that have been elected to fill the aforementioned vacancies, Luke Lokhorst and Lyle Maxson. Their terms on the board began February 14, 2024. Lyle Maxson is at the forefront healthcare innovation including founding and serving as a board member on companies leveraging Artificial Intelligence and plant medicine to push healthcare system forward. Luke Lokhorst holds a Masters Degree in International Business and Sustainable Finance and are excited to add him to the leadership team.Reported Earnings • Nov 24Third quarter 2023 earnings released: US$0.56 loss per share (vs US$0.49 loss in 3Q 2022)Third quarter 2023 results: US$0.56 loss per share (further deteriorated from US$0.49 loss in 3Q 2022). Revenue: US$19.1m (down 13% from 3Q 2022). Net loss: US$1.74m (loss widened 158% from 3Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Personal Products industry in North America.New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Market cap is less than US$10m (CA$1.85m market cap, or US$1.34m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).공시 • Aug 27Irwin Naturals Announces Goodwill Impairment for the Second Quarter Ended June 30, 2023Irwin Naturals Inc. announced Goodwill impairment of $9,112,000 for the second quarter ended June 30, 2023.Reported Earnings • Aug 27Second quarter 2023 earnings released: US$1.57 loss per share (vs US$0.032 profit in 2Q 2022)Second quarter 2023 results: US$1.57 loss per share (down from US$0.032 profit in 2Q 2022). Revenue: US$22.1m (up 1.5% from 2Q 2022). Net loss: US$5.32m (down US$5.36m from profit in 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Personal Products industry in North America.공시 • Jun 03Irwin Naturals, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2023Irwin Naturals, Inc. reported impairment charges for the first quarter ended March 31, 2023. For the period, the company reported goodwill impairment of 2,810,000.Reported Earnings • Jun 03First quarter 2023 earnings released: US$2.27 loss per share (vs US$1.12 profit in 1Q 2022)First quarter 2023 results: US$2.27 loss per share (down from US$1.12 profit in 1Q 2022). Revenue: US$22.5m (flat on 1Q 2022). Net loss: US$7.63m (down US$8.97m from profit in 1Q 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Personal Products industry in North America.Board Change • Jun 03Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Rod Kight is the most experienced director on the board, commencing their role in 2021. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.공시 • Jun 02Irwin Naturals, Inc. Announces Election of Sheri Orlowitz as A New Director of the Company as of May 12, 2023Irwin Naturals, Inc. announced the election of Sheri Orlowitz as a new director of the Company as of May 12, 2023 to fill the vacancy left by the resignation of Mr. Bismuth earlier this month.공시 • Feb 19Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Serenity Health.Irwin Naturals Inc. (CNSX:IWIN) agreed to acquire Serenity Health on November 25, 2022. Under the terms of the transaction, the total consideration will be paid in upfront and deferred consideration. Also included are contingent payments based on milestones related to expansion and profitability goals. The transaction is subject to regulatory approvals. Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Serenity Health on February 18, 2023.공시 • Jan 29Irwin Naturals Inc. (CNSX:IWIN) signed letter of intent to acquire Braxia Scientific Corp. (CNSX:BRAX) for $30 million.Irwin Naturals Inc. (CNSX:IWIN) signed letter of intent to acquire Braxia Scientific Corp. (CNSX:BRAX) for $30 million on January 27, 2023. Under the terms of the LOI, Irwin is prepared to offer a purchase price per Braxia Share based upon a valuation of the outstanding Braxia Shares of $30 million and the purchase price would be payable on closing of the transaction by the issuance of consideration shares to each holder of Braxia shares. The final purchase price per Braxia Share and the exchange ratio will be set forth and determined at the time the arrangement agreement is executed. The number of consideration shares will also be adjusted upward in the event that the total consideration received by holders of Braxia Shares is less than $30 million, to be determined at a specified period of time after the closing date and as set forth in the arrangement agreement. Additionally, under the terms of the LOI and in connection with the transaction, it is expected that the convertible securities of Braxia would, pursuant to the agreement, either remain outstanding in accordance with their terms or be exchanged for substantially similar securities of Irwin. The transaction is subject to, among other things (i) completion of satisfactory due diligence by each of Braxia and Irwin; (ii) negotiation of and the entering into of a binding definitive Arrangement Agreement in connection with the Proposed Transaction; (iii) receipt of all required corporate approvals from the board of directors of Braxia and Irwin, respectively, and all regulatory and shareholder approvals, including the approval of the CSE and any required third-party consents: and (iv) Braxia having at least $0.431 million (CAD 0.575 million) in working capital immediately before closing on the Closing Date.분석 기사 • Dec 13Insufficient Growth At Irwin Naturals Inc. (CSE:IWIN) Hampers Share PriceWhen close to half the companies in Canada have price-to-earnings ratios (or "P/E's") above 11x, you may consider Irwin...Valuation Update With 7 Day Price Move • Dec 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to CA$3.43, the stock trades at a trailing P/E ratio of 3.2x. Average forward P/E is 19x in the Personal Products industry in North America. Total loss to shareholders of 19% over the past year.Reported Earnings • Dec 01Third quarter 2022 earnings released: US$0.45 loss per share (vs US$1.22 loss in 3Q 2021)Third quarter 2022 results: US$0.45 loss per share (improved from US$1.22 loss in 3Q 2021). Revenue: US$22.0m (down 7.0% from 3Q 2021). Net loss: US$673.0k (loss narrowed 54% from 3Q 2021). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Personal Products industry in Canada.공시 • Dec 01Irwin Naturals Inc. (CNSX:IWIN) agreed to acquire Serenity Health.Irwin Naturals Inc. (CNSX:IWIN) agreed to acquire Serenity Health on November 25, 2022. Under the terms of the transaction, the total consideration will be paid in upfront and deferred consideration. Also included are contingent payments based on milestones related to expansion and profitability goals. The transaction is subject to regulatory approvals.Board Change • Nov 16High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Rod Kight is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Nov 10Irwin Naturals Inc. (CNSX:IWIN) signed binding, arms length agreement to acquire Assets of Tri-Cities Infusion & Wellness Clinic, PLLC.Irwin Naturals Inc. (CNSX:IWIN) signed a binding arms length agreement to acquire Assets of Tri-Cities Infusion & Wellness Clinic, PLLC on November 5, 2022. The total consideration is to be paid in stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals.공시 • Nov 02+ 1 more updateIrwin Naturals Announces CFO Board ChangesIrwin Naturals Inc. announced that Philippe Faraut has tendered his resignation as Chief Financial Officer, effective November 1, 2022. Sean Sands, the company’s current Vice President of Finance, will be promoted to fill the role of CFO for Company.Valuation Update With 7 Day Price Move • Oct 20Investor sentiment improved over the past weekAfter last week's 21% share price gain to CA$2.60, the stock trades at a trailing P/E ratio of 2.1x. Average forward P/E is 15x in the Personal Products industry in North America. Total returns to shareholders of 4.0% over the past year.분석 기사 • Oct 18There Are Reasons To Feel Uneasy About Irwin Naturals' (CSE:IWIN) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...공시 • Oct 01Irwin Naturals Inc. (CNSX:IWIN) entered into an agreement to acquire Keta Media, LLC.Irwin Naturals Inc. (CNSX:IWIN) entered into an agreement to acquire Keta Media, LLC on September 29, 2022. The total consideration at closing will be paid in cash consideration, including the assumption of certain debts of Ketamine Media. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The transaction is subject to to certain customary closing condition and regulatory approvals.Valuation Update With 7 Day Price Move • Sep 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to CA$2.48, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 16x in the Personal Products industry in North America. Total returns to shareholders of 10% over the past year.Reported Earnings • Aug 30Second quarter 2022 earnings released: EPS: US$0.032 (vs US$2.83 in 2Q 2021)Second quarter 2022 results: EPS: US$0.032 (down from US$2.83 in 2Q 2021). Revenue: US$21.8m (down 18% from 2Q 2021). Net income: US$39.0k (down 99% from 2Q 2021). Profit margin: 0.2% (down from 11% in 2Q 2021).공시 • Aug 16Irwin Naturals Inc. (CNSX:IWIN) acquired Assets from Hobie Fuerstman DO PLC.Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets from Hobie Fuerstman D O PLC on June 17, 2022. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The agreement is subject to certain customary closing conditions and regulatory approvals. Irwin Naturals Inc. (CNSX:IWIN) acquired Assets from Hobie Fuerstman DO PLC on August 15, 2022. Irwin Naturals will provide sellers cash payments as well as 284,848 subordinate voting shares upon closing. Irwin Naturals Emergence previously acquired five ketamine clinics in Florida, one in Iowa., one in New Hampshire, and two in Georgia.공시 • Aug 09Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Two ketamine clinics in Georgia from Invictus Clinic, LLC.Irwin Naturals Inc. (CNSX:IWIN) entered into a definitive agreement to acquire Two ketamine clinics in Georgia from Invictus Clinic, LLC on June 21, 2022. As consideration for the acquisition, Irwin Naturals will provide sellers cash payments, as well as at least 333,333 Subordinate Voting Shares to be issued no later than January 10, 2023. Furthermore, the transaction includes an additional contingent consideration based on future milestones related to operational and profitability targets, to be satisfied in shares. The clinics are located in Atlanta and Woodstock, Ga., operated under the name of the Invictus Clinic. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The transactions is subject to certain customary closing and regulatory approvals. Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Two ketamine clinics in Georgia from Invictus Clinic, LLC on August 8, 2022.공시 • Jul 29Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Assets of New England Ketamine PLLC.Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets of New England Ketamine PLLC on May 16, 2022. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The transaction is subject to certain customary conditions and regulatory approvals. Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Assets of New England Ketamine PLLC on July 28, 2022. As consideration for the acquisition, the Irwin Naturals has issued 2,692 Proportionate Voting Shares and 31 Subordinate Voting Shares.공시 • Jun 22Irwin Naturals Inc. (CNSX:IWIN) entered into a definitive agreement to acquire Invictus Clinic, LLC.Irwin Naturals Inc. (CNSX:IWIN) entered into a definitive agreement to acquire Invictus Clinic, LLC on June 21, 2022. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The transactions is subject to certain customary closing and regulatory approvals.공시 • Jun 18Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets from Hobie Fuerstman D O PLC.Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets from Hobie Fuerstman D O PLC on June 17, 2022. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The agreement is subject to certain customary closing conditions and regulatory approvals.Reported Earnings • Jun 01First quarter 2022 earnings released: EPS: US$1.12 (vs US$3.72 in 1Q 2021)First quarter 2022 results: EPS: US$1.12 (down from US$3.72 in 1Q 2021). Revenue: US$22.6m (down 6.4% from 1Q 2021). Net income: US$1.34m (down 64% from 1Q 2021). Profit margin: 5.9% (down from 15% in 1Q 2021).공시 • May 22Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of KHC Capital Group, LLC.Irwin Naturals Inc. (CNSX:IWIN) entered into an acquisition agreement to acquire KHC Capital Group, LLC on April 17, 2022. All clinic associated with the KHC Capital Group, LLC will be renamed to Irwin Naturals Emergence. As consideration for the acquisition, Irwin will issue subordinate voting shares (“SVS”) and proportionate voting shares (“PVS”) in the capital of Irwin, equivalent to 1,066,667 SVS on an as-converted to SVS basis and assume or pay off approximately $1,600,000 of debt at closing. In addition members of, Ketamine Health Center’s will be entitled to receive an additional payment equal to the value of 10 times the contracting entities’ 2022 EBITDA less the value of the Closing Consideration Shares at the time of closing to be paid in “SVS” and “PVS” as determined by Irwin will be based on the volume weighted average closing price of the SVS on the facilities of the CSE or such recognized Canadian or other senior stock exchange on which the SVS are then trading for the twenty trading days immediately prior to the date the applicable clinic satisfies the applicable conditions or such other price as may be mandated by the applicable policies of such exchange. The pre-acquisition owners of Ketamine Health Centers will be eligible to receive additional consideration based on certain conditions. If in the first three years after closing, the current Ketamine Health Centers team opens and operates additional clinics (to be branded as Irwin Naturals Emergence clinics) that earn $150,000 in EBITDA on a per clinic basis, on an annualized basis over a 150 day rolling period, the members of Ketamine Health Centers shall earn $250,000 in additional consideration to be paid in SVS and PVS. Such additional consideration is limited to a maximum of 10 additional clinics, and each clinic can only earn the additional consideration one time. Accordingly, up to an additional $2,500,000 of SVS may be issuable. Ketamine Health Center’s management team will remain in place following the acquisition. The agreement is subject to certain customary closing conditions and regulatory approvals. Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of KHC Capital Group, LLC on May 20, 2022. As consideration for the acquisition, Irwin has issued 10,661 Proportionate Voting Shares (“PVS”) and 567 Subordinate Voting Shares (“SVS”), which is equivalent to a total of 1,066,667 SVS on an as-converted to SVS basis (“Closing Consideration Shares”) and is assuming approximately US$1.6 million of debt of which $1 million was repaid at closing. Furthermore, the transaction includes an additional contingent consideration based on future milestones related to operational and profitability targets, to be satisfied in shares.공시 • May 17Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets of New England Ketamine PLLC.Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets of New England Ketamine PLLC on May 16, 2022. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The transaction is subject to certain customary conditions and regulatory approvals.공시 • May 04Irwin Naturals Inc. to Report Q4, 2021 Results on May 03, 2022Irwin Naturals Inc. announced that they will report Q4, 2021 results on May 03, 2022Reported Earnings • May 03Full year 2021 earnings releasedFull year 2021 results: Revenue: US$100.3m (up 12% from FY 2020). Net income: US$8.62m (up 19% from FY 2020). Profit margin: 8.6% (up from 8.1% in FY 2020). The increase in margin was driven by higher revenue.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Apr 19Irwin Naturals Inc. (CNSX:IWIN) entered into an acquisition agreement to acquire KHC Capital Group, LLC.Irwin Naturals Inc. (CNSX:IWIN) entered into an acquisition agreement to acquire KHC Capital Group, LLC on April 17, 2022. All clinic associated with the KHC Capital Group, LLC will be renamed to Irwin Naturals Emergence. As consideration for the acquisition, Irwin will issue subordinate voting shares (“SVS”) and proportionate voting shares (“PVS”) in the capital of Irwin, equivalent to 1,066,667 SVS on an as-converted to SVS basis and assume or pay off approximately $1,600,000 of debt at closing. In addition members of, Ketamine Health Center’s will be entitled to receive an additional payment equal to the value of 10 times the contracting entities’ 2022 EBITDA less the value of the Closing Consideration Shares at the time of closing to be paid in “SVS” and “PVS” as determined by Irwin will be based on the volume weighted average closing price of the SVS on the facilities of the CSE or such recognized Canadian or other senior stock exchange on which the SVS are then trading for the twenty trading days immediately prior to the date the applicable clinic satisfies the applicable conditions or such other price as may be mandated by the applicable policies of such exchange. The pre-acquisition owners of Ketamine Health Centers will be eligible to receive additional consideration based on certain conditions. If in the first three years after closing, the current Ketamine Health Centers team opens and operates additional clinics (to be branded as Irwin Naturals Emergence clinics) that earn $150,000 in EBITDA on a per clinic basis, on an annualized basis over a 150 day rolling period, the members of Ketamine Health Centers shall earn $250,000 in additional consideration to be paid in SVS and PVS. Such additional consideration is limited to a maximum of 10 additional clinics, and each clinic can only earn the additional consideration one time. Accordingly, up to an additional $2,500,000 of SVS may be issuable. Ketamine Health Center’s management team will remain in place following the acquisition. The agreement is subject to certain customary closing conditions and regulatory approvals.분석 기사 • Dec 01Irwin Naturals (CSE:IWIN) Is Posting Promising Earnings But The Good News Doesn’t Stop ThereThe market seemed underwhelmed by the solid earnings posted by Irwin Naturals Inc. ( CSE:IWIN ) recently. Along with...Reported Earnings • Nov 27Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: US$1.22 loss per share. Revenue: US$23.7m (flat on 3Q 2020). Net loss: US$1.47m (flat on 3Q 2020). Revenue was in line with analyst estimates.Board Change • Oct 06No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.주주 수익률IWINCA Personal ProductsCA 시장7D0%4.3%2.8%1Y-77.8%5.0%32.0%전체 주주 수익률 보기수익률 대 산업: IWIN은 지난 1년 동안 5%의 수익을 기록한 Canadian Personal Products 산업보다 저조한 성과를 냈습니다.수익률 대 시장: IWIN은 지난 1년 동안 32%를 기록한 Canadian 시장보다 저조한 성과를 냈습니다.주가 변동성Is IWIN's price volatile compared to industry and market?IWIN volatilityIWIN Average Weekly Movementn/aPersonal Products Industry Average Movement7.7%Market Average Movement10.1%10% most volatile stocks in CA Market17.6%10% least volatile stocks in CA Market3.8%안정적인 주가: IWIN는 지난 3개월 동안 Canadian 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: Insufficient data to determine IWIN의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트n/an/aKlee Irwinwww.irwinnaturals.com는 미국, 캐나다 및 전 세계에서 비타민 및 기타 건강 보조제를 개발 및 유통하는 회사입니다. 이 회사는 CBD 오일, 구미, 소프트 젤, CBD 크림, 발삼 및 롤온, 비타민 및 보충제, 국소 치료제 및 기타 제품을 제공합니다. 또한 정신 건강 클리닉도 운영합니다.더 보기Irwin Naturals, Inc. 기초 지표 요약Irwin Naturals의 순이익과 매출은 시가총액과 어떻게 비교됩니까?IWIN 기초 통계시가총액CA$1.01m순이익 (TTM)-CA$28.29m매출 (TTM)CA$120.26m0.0x주가매출비율(P/S)0.0x주가수익비율(P/E)IWIN는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표IWIN 손익계산서 (TTM)매출US$86.75m매출원가US$48.42m총이익US$38.33m기타 비용US$58.74m순이익-US$20.41m최근 보고된 실적Sep 30, 2023다음 실적 발표일해당 없음주당순이익(EPS)-6.06총이익률44.18%순이익률-23.52%부채/자본 비율269.2%IWIN의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/08/04 19:59종가2024/05/07 00:00수익2023/09/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Irwin Naturals, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Pablo ZuanicCantor Fitzgerald & Co.Patrick TrucchioH.C. Wainwright & Co.Michael OkunewitchMaxim Group1명의 분석가 더 보기
New Risk • Apr 19New major risk - Revenue and earnings growthEarnings have declined by 87% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Shares are highly illiquid. Earnings have declined by 87% per year over the past 5 years. Market cap is less than US$10m (CA$471.7k market cap, or US$343.2k).
Board Change • Apr 11No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman & CEO Klee Irwin is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
공시 • Mar 30+ 1 more updateIrwin Naturals, Inc. Announces Directors ChangesIrwin Naturals, Inc. announced that Rod Kight and Sheri Orlowitz have tendered their resignations as directors of the Company effective February 14, 2024 . The Company thanks Mr. Kight and Ms. Orlowitz for their contributions to the Company and wishes them the best of luck in their future endeavors. Klee Irwin will remain as chairman of the Board of Directors. Moreover, the Company announced the new board members that have been elected to fill the aforementioned vacancies, Luke Lokhorst and Lyle Maxson. Their terms on the board began February 14, 2024. Lyle Maxson is at the forefront healthcare innovation including founding and serving as a board member on companies leveraging Artificial Intelligence and plant medicine to push healthcare system forward. Luke Lokhorst holds a Masters Degree in International Business and Sustainable Finance and are excited to add him to the leadership team.
Reported Earnings • Nov 24Third quarter 2023 earnings released: US$0.56 loss per share (vs US$0.49 loss in 3Q 2022)Third quarter 2023 results: US$0.56 loss per share (further deteriorated from US$0.49 loss in 3Q 2022). Revenue: US$19.1m (down 13% from 3Q 2022). Net loss: US$1.74m (loss widened 158% from 3Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Personal Products industry in North America.
New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Market cap is less than US$10m (CA$1.85m market cap, or US$1.34m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).
공시 • Aug 27Irwin Naturals Announces Goodwill Impairment for the Second Quarter Ended June 30, 2023Irwin Naturals Inc. announced Goodwill impairment of $9,112,000 for the second quarter ended June 30, 2023.
New Risk • Apr 19New major risk - Revenue and earnings growthEarnings have declined by 87% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Shares are highly illiquid. Earnings have declined by 87% per year over the past 5 years. Market cap is less than US$10m (CA$471.7k market cap, or US$343.2k).
Board Change • Apr 11No independent directorsThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman & CEO Klee Irwin is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
공시 • Mar 30+ 1 more updateIrwin Naturals, Inc. Announces Directors ChangesIrwin Naturals, Inc. announced that Rod Kight and Sheri Orlowitz have tendered their resignations as directors of the Company effective February 14, 2024 . The Company thanks Mr. Kight and Ms. Orlowitz for their contributions to the Company and wishes them the best of luck in their future endeavors. Klee Irwin will remain as chairman of the Board of Directors. Moreover, the Company announced the new board members that have been elected to fill the aforementioned vacancies, Luke Lokhorst and Lyle Maxson. Their terms on the board began February 14, 2024. Lyle Maxson is at the forefront healthcare innovation including founding and serving as a board member on companies leveraging Artificial Intelligence and plant medicine to push healthcare system forward. Luke Lokhorst holds a Masters Degree in International Business and Sustainable Finance and are excited to add him to the leadership team.
Reported Earnings • Nov 24Third quarter 2023 earnings released: US$0.56 loss per share (vs US$0.49 loss in 3Q 2022)Third quarter 2023 results: US$0.56 loss per share (further deteriorated from US$0.49 loss in 3Q 2022). Revenue: US$19.1m (down 13% from 3Q 2022). Net loss: US$1.74m (loss widened 158% from 3Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Personal Products industry in North America.
New Risk • Nov 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Shareholders have been substantially diluted in the past year (76% increase in shares outstanding). Market cap is less than US$10m (CA$1.85m market cap, or US$1.34m). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change).
공시 • Aug 27Irwin Naturals Announces Goodwill Impairment for the Second Quarter Ended June 30, 2023Irwin Naturals Inc. announced Goodwill impairment of $9,112,000 for the second quarter ended June 30, 2023.
Reported Earnings • Aug 27Second quarter 2023 earnings released: US$1.57 loss per share (vs US$0.032 profit in 2Q 2022)Second quarter 2023 results: US$1.57 loss per share (down from US$0.032 profit in 2Q 2022). Revenue: US$22.1m (up 1.5% from 2Q 2022). Net loss: US$5.32m (down US$5.36m from profit in 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Personal Products industry in North America.
공시 • Jun 03Irwin Naturals, Inc. Reports Impairment Charges for the First Quarter Ended March 31, 2023Irwin Naturals, Inc. reported impairment charges for the first quarter ended March 31, 2023. For the period, the company reported goodwill impairment of 2,810,000.
Reported Earnings • Jun 03First quarter 2023 earnings released: US$2.27 loss per share (vs US$1.12 profit in 1Q 2022)First quarter 2023 results: US$2.27 loss per share (down from US$1.12 profit in 1Q 2022). Revenue: US$22.5m (flat on 1Q 2022). Net loss: US$7.63m (down US$8.97m from profit in 1Q 2022). Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Personal Products industry in North America.
Board Change • Jun 03Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Rod Kight is the most experienced director on the board, commencing their role in 2021. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
공시 • Jun 02Irwin Naturals, Inc. Announces Election of Sheri Orlowitz as A New Director of the Company as of May 12, 2023Irwin Naturals, Inc. announced the election of Sheri Orlowitz as a new director of the Company as of May 12, 2023 to fill the vacancy left by the resignation of Mr. Bismuth earlier this month.
공시 • Feb 19Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Serenity Health.Irwin Naturals Inc. (CNSX:IWIN) agreed to acquire Serenity Health on November 25, 2022. Under the terms of the transaction, the total consideration will be paid in upfront and deferred consideration. Also included are contingent payments based on milestones related to expansion and profitability goals. The transaction is subject to regulatory approvals. Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Serenity Health on February 18, 2023.
공시 • Jan 29Irwin Naturals Inc. (CNSX:IWIN) signed letter of intent to acquire Braxia Scientific Corp. (CNSX:BRAX) for $30 million.Irwin Naturals Inc. (CNSX:IWIN) signed letter of intent to acquire Braxia Scientific Corp. (CNSX:BRAX) for $30 million on January 27, 2023. Under the terms of the LOI, Irwin is prepared to offer a purchase price per Braxia Share based upon a valuation of the outstanding Braxia Shares of $30 million and the purchase price would be payable on closing of the transaction by the issuance of consideration shares to each holder of Braxia shares. The final purchase price per Braxia Share and the exchange ratio will be set forth and determined at the time the arrangement agreement is executed. The number of consideration shares will also be adjusted upward in the event that the total consideration received by holders of Braxia Shares is less than $30 million, to be determined at a specified period of time after the closing date and as set forth in the arrangement agreement. Additionally, under the terms of the LOI and in connection with the transaction, it is expected that the convertible securities of Braxia would, pursuant to the agreement, either remain outstanding in accordance with their terms or be exchanged for substantially similar securities of Irwin. The transaction is subject to, among other things (i) completion of satisfactory due diligence by each of Braxia and Irwin; (ii) negotiation of and the entering into of a binding definitive Arrangement Agreement in connection with the Proposed Transaction; (iii) receipt of all required corporate approvals from the board of directors of Braxia and Irwin, respectively, and all regulatory and shareholder approvals, including the approval of the CSE and any required third-party consents: and (iv) Braxia having at least $0.431 million (CAD 0.575 million) in working capital immediately before closing on the Closing Date.
분석 기사 • Dec 13Insufficient Growth At Irwin Naturals Inc. (CSE:IWIN) Hampers Share PriceWhen close to half the companies in Canada have price-to-earnings ratios (or "P/E's") above 11x, you may consider Irwin...
Valuation Update With 7 Day Price Move • Dec 13Investor sentiment improved over the past weekAfter last week's 16% share price gain to CA$3.43, the stock trades at a trailing P/E ratio of 3.2x. Average forward P/E is 19x in the Personal Products industry in North America. Total loss to shareholders of 19% over the past year.
Reported Earnings • Dec 01Third quarter 2022 earnings released: US$0.45 loss per share (vs US$1.22 loss in 3Q 2021)Third quarter 2022 results: US$0.45 loss per share (improved from US$1.22 loss in 3Q 2021). Revenue: US$22.0m (down 7.0% from 3Q 2021). Net loss: US$673.0k (loss narrowed 54% from 3Q 2021). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Personal Products industry in Canada.
공시 • Dec 01Irwin Naturals Inc. (CNSX:IWIN) agreed to acquire Serenity Health.Irwin Naturals Inc. (CNSX:IWIN) agreed to acquire Serenity Health on November 25, 2022. Under the terms of the transaction, the total consideration will be paid in upfront and deferred consideration. Also included are contingent payments based on milestones related to expansion and profitability goals. The transaction is subject to regulatory approvals.
Board Change • Nov 16High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Director Rod Kight is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Nov 10Irwin Naturals Inc. (CNSX:IWIN) signed binding, arms length agreement to acquire Assets of Tri-Cities Infusion & Wellness Clinic, PLLC.Irwin Naturals Inc. (CNSX:IWIN) signed a binding arms length agreement to acquire Assets of Tri-Cities Infusion & Wellness Clinic, PLLC on November 5, 2022. The total consideration is to be paid in stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals.
공시 • Nov 02+ 1 more updateIrwin Naturals Announces CFO Board ChangesIrwin Naturals Inc. announced that Philippe Faraut has tendered his resignation as Chief Financial Officer, effective November 1, 2022. Sean Sands, the company’s current Vice President of Finance, will be promoted to fill the role of CFO for Company.
Valuation Update With 7 Day Price Move • Oct 20Investor sentiment improved over the past weekAfter last week's 21% share price gain to CA$2.60, the stock trades at a trailing P/E ratio of 2.1x. Average forward P/E is 15x in the Personal Products industry in North America. Total returns to shareholders of 4.0% over the past year.
분석 기사 • Oct 18There Are Reasons To Feel Uneasy About Irwin Naturals' (CSE:IWIN) Returns On CapitalFinding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
공시 • Oct 01Irwin Naturals Inc. (CNSX:IWIN) entered into an agreement to acquire Keta Media, LLC.Irwin Naturals Inc. (CNSX:IWIN) entered into an agreement to acquire Keta Media, LLC on September 29, 2022. The total consideration at closing will be paid in cash consideration, including the assumption of certain debts of Ketamine Media. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The transaction is subject to to certain customary closing condition and regulatory approvals.
Valuation Update With 7 Day Price Move • Sep 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to CA$2.48, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 16x in the Personal Products industry in North America. Total returns to shareholders of 10% over the past year.
Reported Earnings • Aug 30Second quarter 2022 earnings released: EPS: US$0.032 (vs US$2.83 in 2Q 2021)Second quarter 2022 results: EPS: US$0.032 (down from US$2.83 in 2Q 2021). Revenue: US$21.8m (down 18% from 2Q 2021). Net income: US$39.0k (down 99% from 2Q 2021). Profit margin: 0.2% (down from 11% in 2Q 2021).
공시 • Aug 16Irwin Naturals Inc. (CNSX:IWIN) acquired Assets from Hobie Fuerstman DO PLC.Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets from Hobie Fuerstman D O PLC on June 17, 2022. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The agreement is subject to certain customary closing conditions and regulatory approvals. Irwin Naturals Inc. (CNSX:IWIN) acquired Assets from Hobie Fuerstman DO PLC on August 15, 2022. Irwin Naturals will provide sellers cash payments as well as 284,848 subordinate voting shares upon closing. Irwin Naturals Emergence previously acquired five ketamine clinics in Florida, one in Iowa., one in New Hampshire, and two in Georgia.
공시 • Aug 09Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Two ketamine clinics in Georgia from Invictus Clinic, LLC.Irwin Naturals Inc. (CNSX:IWIN) entered into a definitive agreement to acquire Two ketamine clinics in Georgia from Invictus Clinic, LLC on June 21, 2022. As consideration for the acquisition, Irwin Naturals will provide sellers cash payments, as well as at least 333,333 Subordinate Voting Shares to be issued no later than January 10, 2023. Furthermore, the transaction includes an additional contingent consideration based on future milestones related to operational and profitability targets, to be satisfied in shares. The clinics are located in Atlanta and Woodstock, Ga., operated under the name of the Invictus Clinic. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The transactions is subject to certain customary closing and regulatory approvals. Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Two ketamine clinics in Georgia from Invictus Clinic, LLC on August 8, 2022.
공시 • Jul 29Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Assets of New England Ketamine PLLC.Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets of New England Ketamine PLLC on May 16, 2022. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The transaction is subject to certain customary conditions and regulatory approvals. Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of Assets of New England Ketamine PLLC on July 28, 2022. As consideration for the acquisition, the Irwin Naturals has issued 2,692 Proportionate Voting Shares and 31 Subordinate Voting Shares.
공시 • Jun 22Irwin Naturals Inc. (CNSX:IWIN) entered into a definitive agreement to acquire Invictus Clinic, LLC.Irwin Naturals Inc. (CNSX:IWIN) entered into a definitive agreement to acquire Invictus Clinic, LLC on June 21, 2022. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The transactions is subject to certain customary closing and regulatory approvals.
공시 • Jun 18Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets from Hobie Fuerstman D O PLC.Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets from Hobie Fuerstman D O PLC on June 17, 2022. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The agreement is subject to certain customary closing conditions and regulatory approvals.
Reported Earnings • Jun 01First quarter 2022 earnings released: EPS: US$1.12 (vs US$3.72 in 1Q 2021)First quarter 2022 results: EPS: US$1.12 (down from US$3.72 in 1Q 2021). Revenue: US$22.6m (down 6.4% from 1Q 2021). Net income: US$1.34m (down 64% from 1Q 2021). Profit margin: 5.9% (down from 15% in 1Q 2021).
공시 • May 22Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of KHC Capital Group, LLC.Irwin Naturals Inc. (CNSX:IWIN) entered into an acquisition agreement to acquire KHC Capital Group, LLC on April 17, 2022. All clinic associated with the KHC Capital Group, LLC will be renamed to Irwin Naturals Emergence. As consideration for the acquisition, Irwin will issue subordinate voting shares (“SVS”) and proportionate voting shares (“PVS”) in the capital of Irwin, equivalent to 1,066,667 SVS on an as-converted to SVS basis and assume or pay off approximately $1,600,000 of debt at closing. In addition members of, Ketamine Health Center’s will be entitled to receive an additional payment equal to the value of 10 times the contracting entities’ 2022 EBITDA less the value of the Closing Consideration Shares at the time of closing to be paid in “SVS” and “PVS” as determined by Irwin will be based on the volume weighted average closing price of the SVS on the facilities of the CSE or such recognized Canadian or other senior stock exchange on which the SVS are then trading for the twenty trading days immediately prior to the date the applicable clinic satisfies the applicable conditions or such other price as may be mandated by the applicable policies of such exchange. The pre-acquisition owners of Ketamine Health Centers will be eligible to receive additional consideration based on certain conditions. If in the first three years after closing, the current Ketamine Health Centers team opens and operates additional clinics (to be branded as Irwin Naturals Emergence clinics) that earn $150,000 in EBITDA on a per clinic basis, on an annualized basis over a 150 day rolling period, the members of Ketamine Health Centers shall earn $250,000 in additional consideration to be paid in SVS and PVS. Such additional consideration is limited to a maximum of 10 additional clinics, and each clinic can only earn the additional consideration one time. Accordingly, up to an additional $2,500,000 of SVS may be issuable. Ketamine Health Center’s management team will remain in place following the acquisition. The agreement is subject to certain customary closing conditions and regulatory approvals. Irwin Naturals Inc. (CNSX:IWIN) completed the acquisition of KHC Capital Group, LLC on May 20, 2022. As consideration for the acquisition, Irwin has issued 10,661 Proportionate Voting Shares (“PVS”) and 567 Subordinate Voting Shares (“SVS”), which is equivalent to a total of 1,066,667 SVS on an as-converted to SVS basis (“Closing Consideration Shares”) and is assuming approximately US$1.6 million of debt of which $1 million was repaid at closing. Furthermore, the transaction includes an additional contingent consideration based on future milestones related to operational and profitability targets, to be satisfied in shares.
공시 • May 17Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets of New England Ketamine PLLC.Irwin Naturals Inc. (CNSX:IWIN) entered into a binding agreement to acquire Assets of New England Ketamine PLLC on May 16, 2022. The total consideration is to be paid in a combination of cash and stock, with the maximum payable contingent on a number of milestones related to profitability and operational goals. The transaction is subject to certain customary conditions and regulatory approvals.
공시 • May 04Irwin Naturals Inc. to Report Q4, 2021 Results on May 03, 2022Irwin Naturals Inc. announced that they will report Q4, 2021 results on May 03, 2022
Reported Earnings • May 03Full year 2021 earnings releasedFull year 2021 results: Revenue: US$100.3m (up 12% from FY 2020). Net income: US$8.62m (up 19% from FY 2020). Profit margin: 8.6% (up from 8.1% in FY 2020). The increase in margin was driven by higher revenue.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Apr 19Irwin Naturals Inc. (CNSX:IWIN) entered into an acquisition agreement to acquire KHC Capital Group, LLC.Irwin Naturals Inc. (CNSX:IWIN) entered into an acquisition agreement to acquire KHC Capital Group, LLC on April 17, 2022. All clinic associated with the KHC Capital Group, LLC will be renamed to Irwin Naturals Emergence. As consideration for the acquisition, Irwin will issue subordinate voting shares (“SVS”) and proportionate voting shares (“PVS”) in the capital of Irwin, equivalent to 1,066,667 SVS on an as-converted to SVS basis and assume or pay off approximately $1,600,000 of debt at closing. In addition members of, Ketamine Health Center’s will be entitled to receive an additional payment equal to the value of 10 times the contracting entities’ 2022 EBITDA less the value of the Closing Consideration Shares at the time of closing to be paid in “SVS” and “PVS” as determined by Irwin will be based on the volume weighted average closing price of the SVS on the facilities of the CSE or such recognized Canadian or other senior stock exchange on which the SVS are then trading for the twenty trading days immediately prior to the date the applicable clinic satisfies the applicable conditions or such other price as may be mandated by the applicable policies of such exchange. The pre-acquisition owners of Ketamine Health Centers will be eligible to receive additional consideration based on certain conditions. If in the first three years after closing, the current Ketamine Health Centers team opens and operates additional clinics (to be branded as Irwin Naturals Emergence clinics) that earn $150,000 in EBITDA on a per clinic basis, on an annualized basis over a 150 day rolling period, the members of Ketamine Health Centers shall earn $250,000 in additional consideration to be paid in SVS and PVS. Such additional consideration is limited to a maximum of 10 additional clinics, and each clinic can only earn the additional consideration one time. Accordingly, up to an additional $2,500,000 of SVS may be issuable. Ketamine Health Center’s management team will remain in place following the acquisition. The agreement is subject to certain customary closing conditions and regulatory approvals.
분석 기사 • Dec 01Irwin Naturals (CSE:IWIN) Is Posting Promising Earnings But The Good News Doesn’t Stop ThereThe market seemed underwhelmed by the solid earnings posted by Irwin Naturals Inc. ( CSE:IWIN ) recently. Along with...
Reported Earnings • Nov 27Third quarter 2021 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2021 results: US$1.22 loss per share. Revenue: US$23.7m (flat on 3Q 2020). Net loss: US$1.47m (flat on 3Q 2020). Revenue was in line with analyst estimates.
Board Change • Oct 06No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
